All Outputs (2)

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome (2020)
Journal Article
Javed, Z., Papageorgiou, M., Madden, L. A., Rigby, A. S., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2020). The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome. Endocrine Connections, 9(6), 563-569. https://doi.org/10.1530/EC-20-0173

Context: Endothelial microparticles (EMPs) are novel, surrogate biomarkers of endothelial function and have been shown to be elevated in women with polycystic ovary syndrome (PCOS). It remains poorly understood how pharmacological options for managin... Read More about The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome.

The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects (2019)
Journal Article
Al-Qaissi, A., Alqarni, S., Javed, Z., Atkin, S. L., Sathyapalan, T., Vince, R., & Madden, L. A. (2019). The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. Endocrine, https://doi.org/10.1007/s12020-019-02059-9

© 2019, The Author(s). Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals... Read More about The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects.